PMGC Holdings (ELAB) Change in Inventory (2022 - 2026)
PMGC Holdings (ELAB) posted Change in Inventory of $114570.0 for Q1 2026, up 590.22% sequentially from -$23371.0 in Q4 2025, and up 598.87% YoY from $16393.7 in Q1 2025.
PMGC Holdings (ELAB) Change in Inventory (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Change in Inventory for 5 years, with the latest figure at $114570.0 in Q1 2026.
- Quarterly Change in Inventory rose 598.87% year-over-year to $114570.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10332.0 (up 85.04% YoY) and the FY2025 annual result came in at -$147868.0, down 136.66% from the prior year.
- Change in Inventory grew to $114570.0 in Q1 2026 per ELAB's latest filing, from -$23371.0 in the prior quarter.
- Over five years, Change in Inventory peaked at $449397.0 in Q1 2024 and troughed at -$19.8 million in Q4 2022.
- A 5-year average of -$1.5 million and a median of $7873.0 in 2024 frame the typical range for Change in Inventory.
- The sharpest annual moves came in 2024 and 2026: Change in Inventory plunged 2301.4% in 2024, then surged 598.87% in 2026.
- Over 5 years, Change in Inventory stood at -$19.8 million in 2022, then jumped by 99.98% to -$3642.0 in 2023, then slumped by 2301.4% to -$87459.0 in 2024, then soared by 73.28% to -$23371.0 in 2025, then surged by 590.22% to $114570.0 in 2026.
- According to Business Quant data, Change in Inventory over the past three periods registered $114570.0, -$23371.0, and -$101531.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 28.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 132.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 47.15 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -280,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 135.26 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 12.97 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 164,339.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 114,570.00 |
| Mar 31, 2026 | 114,570.00 |
| Dec 31, 2025 | -23,371.00 |
| Dec 31, 2025 | -23,371.00 |
| Sep 30, 2025 | -101,531.00 |
| Sep 30, 2025 | -101,531.00 |
| Mar 31, 2025 | -22,966.00 |
| Mar 31, 2025 | -22,966.00 |
| Dec 31, 2024 | -87,459.00 |
| Dec 31, 2024 | -87,459.00 |
| Sep 30, 2024 | 7,873.00 |
| Sep 30, 2024 | 7,873.00 |
| Jun 30, 2024 | 33,484.00 |
| Jun 30, 2024 | 33,484.00 |
| Mar 31, 2024 | 449,397.00 |
| Mar 31, 2024 | 449,397.00 |
| Dec 31, 2023 | -3,642.00 |
| Dec 31, 2023 | -3,642.00 |
| Sep 30, 2023 | 21,446.00 |
| Sep 30, 2023 | 21,446.00 |